FXYD5 (FXYD domain containing ion transport regulator 5)
2008-07-01 Setsuo Hirohashi AffiliationPathology Division, National Cancer Center Research Institute 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
Identity
HGNC
LOCATION
19q13.12
LOCUSID
ALIAS
DYSAD,HSPC113,IWU1,KCT1,OIT2,PRO6241,RIC
FUSION GENES
DNA/RNA
Transcription
0.9 kb mRNA; 534 bp open reading frame.
Proteins
Dysadherin protein consists of 178 amino acids.
Description
The deduced amino acid sequence consisted of two hydrophobic regions corresponding to a signal peptide and a transmembrane domain (146-162), a serine-, threonine-, and proline-rich extracellular domain, which is a target for O-glycosylation, anda short cytoplasmic region containing positively charged amino acid residues.
Expression
Endothelial cell, T lymphocytes, basal cell of squamous epithelium.
Localisation
Cell membrane
Homology
The transmembrane domain of dysadherin and mouse RIC especially showed a very high degree of similarity to other ion channels such as Mat-8 chloride channel, phospholemman, which is the major plasma membrane substrate for cAMPdependent protein kinase and protein kinase C, and the subunit of Na, K-ATPase.
Implicated in
Entity name
Various cancers
Disease
Dysadherin, newly identified cell membrane glycoprotein, downregulates E-cadherin and promotes cancer invasion and metastasis. A reverse correlation between dysadherin expression and E-cadherin expression was observed in various cancers. Increased dysadherin expression was correlated with poor prognosis with head and neck squamous cell carcinoma, esophageal carcinoma, gastric carcinoma, colorectal carcinoma, melanoma and so on. Dysadherin expression in epitheloid sarcomas could be a used as powerful diagnostic marker for distinguishing epithelioid sarcomas from malignant rabdoid tumors.
Article Bibliography
| Pubmed ID | Last Year | Title | Authors |
|---|---|---|---|
| 12618882 | 2003 | Prognostic significance of dysadherin expression in advanced colorectal carcinoma. | Aoki S et al |
| 17437014 | 2007 | In breast carcinoma dysadherin expression is correlated with invasiveness but not with E-cadherin. | Batistatou A et al |
| 17690250 | 2007 | Nuclear targeting of the growth hormone receptor results in dysregulation of cell proliferation and tumorigenesis. | Conway-Campbell BL et al |
| 12841864 | 2003 | Cell adhesion system and human cancer morphogenesis. | Hirohashi S et al |
| 11756660 | 2002 | Dysadherin, a cancer-associated cell membrane glycoprotein, down-regulates E-cadherin and promotes metastasis. | Ino Y et al |
| 17197923 | 2007 | Dysadherin expression as a significant prognostic factor and as a determinant of histologic features in synovial sarcoma: special reference to its inverse relationship with E-cadherin expression. | Izumi T et al |
| 16434892 | 2006 | Dysadherin expression in head and neck squamous cell carcinoma: association with lymphangiogenesis and prognostic significance. | Kyzas PA et al |
| 15536331 | 2004 | Prognostic significance of dysadherin expression in tongue cancer: immunohistochemical analysis of 91 cases. | Nakanishi Y et al |
| 17442482 | 2007 | Dysadherin: a new player in cancer progression. | Nam JS et al |
| 16849564 | 2006 | Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells. | Nam JS et al |
| 15751018 | 2005 | Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients. | Nishizawa A et al |
| 12970317 | 2003 | Dysadherin: expression and clinical significance in thyroid carcinoma. | Sato H et al |
| 15459499 | 2004 | Prognostic significance of dysadherin expression in esophageal squamous cell carcinoma. | Shimada Y et al |
| 15102690 | 2004 | Clinical significance of dysadherin expression in gastric cancer patients. | Shimada Y et al |
| 15466191 | 2004 | Dysadherin expression facilitates cell motility and metastatic potential of human pancreatic cancer cells. | Shimamura T et al |
| 16153922 | 2005 | Prognostic significance of dysadherin expression in patients with non-small cell lung cancer. | Tamura M et al |
| 12672699 | 2003 | Aberrant O-glycosylation inhibits stable expression of dysadherin, a carcinoma-associated antigen, and facilitates cell-cell adhesion. | Tsuiji H et al |
| 15619642 | 2004 | Prognostic significance of dysadherin expression in cervical squamous cell carcinoma. | Wu D et al |
| 15245593 | 2004 | Establishment of two cell lines from human gastric scirrhous carcinoma that possess the potential to metastasize spontaneously in nude mice. | Yanagihara K et al |
Other Information
Locus ID:
NCBI: 53827
MIM: 606669
HGNC: 4029
Ensembl: ENSG00000089327
Variants:
dbSNP: 53827
ClinVar: 53827
TCGA: ENSG00000089327
COSMIC: FXYD5
RNA/Proteins
Expression (GTEx)
Protein levels (Protein atlas)
References
| Pubmed ID | Year | Title | Citations |
|---|---|---|---|
| 38725858 | 2024 | The dysadherin/FAK axis promotes individual cell migration in colon cancer. | 0 |
| 38725858 | 2024 | The dysadherin/FAK axis promotes individual cell migration in colon cancer. | 0 |
| 36982661 | 2023 | High-Intensity Training Represses FXYD5 and Glycosylates Na,K-ATPase in Type II Muscle Fibres, Which Are Linked with Improved Muscle K(+) Handling and Performance. | 2 |
| 36982661 | 2023 | High-Intensity Training Represses FXYD5 and Glycosylates Na,K-ATPase in Type II Muscle Fibres, Which Are Linked with Improved Muscle K(+) Handling and Performance. | 2 |
| 35673579 | 2022 | Dysadherin awakens mechanical forces and promotes colorectal cancer progression. | 2 |
| 35977595 | 2022 | FXYD5 promotes sorafenib resistance through the Akt/mTOR signaling pathway in hepatocellular carcinoma. | 5 |
| 35673579 | 2022 | Dysadherin awakens mechanical forces and promotes colorectal cancer progression. | 2 |
| 35977595 | 2022 | FXYD5 promotes sorafenib resistance through the Akt/mTOR signaling pathway in hepatocellular carcinoma. | 5 |
| 31746425 | 2020 | A FXYD5/TGF‑β/SMAD positive feedback loop drives epithelial‑to‑mesenchymal transition and promotes tumor growth and metastasis in ovarian cancer. | 18 |
| 31746425 | 2020 | A FXYD5/TGF‑β/SMAD positive feedback loop drives epithelial‑to‑mesenchymal transition and promotes tumor growth and metastasis in ovarian cancer. | 18 |
| 31434988 | 2019 | FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients. | 23 |
| 31434988 | 2019 | FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients. | 23 |
| 26410457 | 2016 | FXYD1 negatively regulates Na(+)/K(+)-ATPase activity in lung alveolar epithelial cells. | 11 |
| 27006401 | 2016 | FXYD5 Protein Has a Pro-inflammatory Role in Epithelial Cells. | 9 |
| 27142834 | 2016 | The O-glycosylated ectodomain of FXYD5 impairs adhesion by disrupting cell-cell trans-dimerization of Na,K-ATPase β1 subunits. | 16 |
Citation
Setsuo Hirohashi
FXYD5 (FXYD domain containing ion transport regulator 5)
Atlas Genet Cytogenet Oncol Haematol. 2008-07-01
Online version: http://atlasgeneticsoncology.org/gene/40652/fxyd5
